Oyster Pharma Sees $93M Funding Round For Dry Eye Drugs
Oyster Point Pharma Inc. snapped up $93 million in a recent funding round that will be used to ramp up the development of treatments for dry eye disease, the New Jersey-based...To view the full article, register now.
Already a subscriber? Click here to view full article